[go: up one dir, main page]

WO2009077551A1 - Process for preparing risperidone - Google Patents

Process for preparing risperidone Download PDF

Info

Publication number
WO2009077551A1
WO2009077551A1 PCT/EP2008/067691 EP2008067691W WO2009077551A1 WO 2009077551 A1 WO2009077551 A1 WO 2009077551A1 EP 2008067691 W EP2008067691 W EP 2008067691W WO 2009077551 A1 WO2009077551 A1 WO 2009077551A1
Authority
WO
WIPO (PCT)
Prior art keywords
risperidone
temperature
formula
water
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/067691
Other languages
French (fr)
Inventor
Ronny Vanierschot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of WO2009077551A1 publication Critical patent/WO2009077551A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Definitions

  • the present invention concerns an improved process of preparing risperidone (I).
  • Risperidone (I) may be prepared by a variety of processes.
  • EP-0, 196, 132 discloses the preparation of risperidone (I) byN-alkylation of a piperidine intermediate of formula (II) with an alkylating agent of formula (III).
  • risperidone (I) is prepared by an intramolecular aromatic substitution reaction of a compound of formula (IV) in the presence of a base in a solvent mixture of toluene and water.
  • This strained aminal compound (V) was hard to purify and isolate as a solid. Presumably the compound (V) hydrolysed to an aldehyde (VI) which could decompose into a variety of other contaminants.
  • the invention is therefore concerned with a process for preparing risperidone of formula (I) -A-
  • the reaction can conveniently be conducted in stainless steel or enamel or glass- lined equipment provided that the oxygen concentration is constantly maintained above 0.1 %.
  • the remainder of the atmosphere may be either argon or nitrogen or any mixture thereof.
  • the oxygen concentration is preferably from 1 % to 8 %.
  • the conversion reaction of compound (IV) is preferably conducted at a temperature above 80 0 C for 4 to 5 hours.
  • Suitable bases in the reaction are alkali metal hydroxides, preferably potassium hydroxide (KOH).
  • the process comprises the steps of a) charging a reaction vessel with toluene and KOH; b) adding water to the suspension obtained in a) while keeping the temperature between 30 and 40 °C; c) adjusting the concentration of oxygen in the atmosphere of the reaction vessel to between 1 and 8 %; d) adding an intermediate of formula (IV) while keeping the temperature above 30 0 C; e) heating the reaction mixture to a temperature above 80 0 C for 4 to 5 hours; f) diluting the reaction mixture with water at a temperature of 80 0 C; g) separating the water phase; h) extracting the organic layer three times with water at a temperature of 80 0 C; i) cooling the organic layer to a temperature between 0 and 10 0 C while stirring for
  • Risperidone (I) prepared according to the above process does not contain the contaminant product (V) and thus is useful for the preparation of drug product such as risperi- done long acting injection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention concerns an improved process of preparing risperidone (I).

Description

PROCESS FOR PREPARING RISPERIDONE
The present invention concerns an improved process of preparing risperidone (I).
Risperidone (I) may be prepared by a variety of processes. EP-0, 196, 132 discloses the preparation of risperidone (I) byN-alkylation of a piperidine intermediate of formula (II) with an alkylating agent of formula (III).
Figure imgf000002_0001
A higher yielding process was developed thereafter which is disclosed in ES-2006888. Herein, risperidone (I) is prepared by an intramolecular aromatic substitution reaction of a compound of formula (IV) in the presence of a base in a solvent mixture of toluene and water.
Figure imgf000002_0002
Using this process, occasionally batches have been produced that had to be destroyed because they contained decomposition products which appeared after intermediate (IV) had been converted into risperidone (I). Screening experiments showed that the decomposition was markedly enhanced in the presence of stainless steel shavings. In particular a fluorescent product formed which was isolated by column chromatography and identified by mass spectrometry and nuclear magnetic resonance to be compound (V). Rl 16889
Figure imgf000003_0001
(V)
This strained aminal compound (V) was hard to purify and isolate as a solid. Presumably the compound (V) hydrolysed to an aldehyde (VI) which could decompose into a variety of other contaminants.
Figure imgf000003_0002
Compounds (V), (VI) and further degradation products therefrom, are potentially toxic and render the risperidone (I) batches in which they occur unsuitable for conversion into drug products, in particular the risperidone long acting injection sold under the trademark Risperdal® Consta®.
Possibly a radical mechanism catalyzed by Fe 2+ cations may explain the formation of compound (V). In the scheme below R represents a radical of formula (VII)
Figure imgf000003_0003
(vπ)
Figure imgf000004_0001
Subsequent investigations have shown that whilst stainless steel catalyzes the formation of compound (V), it is probably not the root cause. Decomposition rates vary highly amongst different batches and may be in the range of from 5 to 15 % after 24 h reflux. No apparent correlation could be found between residual iron levels and extent of decomposition. Nor does a change from stainless steel equipment to enamel equipment improve the outcome of the process.
It has now unexpectedly been found that decomposition of risperidone (I) can be prevented by reacting an intermediate of Formula (IV) under an atmosphere comprising oxygen. Under an oxygen- free atmosphere, risperidone (I) when prepared from (IV) always decomposes to at least some extent.
The invention is therefore concerned with a process for preparing risperidone of formula (I) -A-
Figure imgf000005_0001
comprising the steps of reacting an intermediate of formula (IV)
Figure imgf000005_0002
in the presence of a base and a solvent mixture comprising toluene and water, and isolating the risperidone of formula (I) formed during the reaction, characterized in that the reaction is conducted under an atmosphere comprising from 0.1 to 8 % of oxygen.
The reaction can conveniently be conducted in stainless steel or enamel or glass- lined equipment provided that the oxygen concentration is constantly maintained above 0.1 %. The remainder of the atmosphere may be either argon or nitrogen or any mixture thereof. The oxygen concentration is preferably from 1 % to 8 %.
The conversion reaction of compound (IV) is preferably conducted at a temperature above 80 0C for 4 to 5 hours. Suitable bases in the reaction are alkali metal hydroxides, preferably potassium hydroxide (KOH).
Relative to the amount of the intermediate of formula (IV), the amount of KOH ranges from 4.0 to 4.6 mol/mol; water ranges from 0.25 to 0.35 L/mol; and toluene ranges from 1.3 to 1.5 L/mol. In particular, the process comprises the steps of a) charging a reaction vessel with toluene and KOH; b) adding water to the suspension obtained in a) while keeping the temperature between 30 and 40 °C; c) adjusting the concentration of oxygen in the atmosphere of the reaction vessel to between 1 and 8 %; d) adding an intermediate of formula (IV) while keeping the temperature above 30 0C; e) heating the reaction mixture to a temperature above 80 0C for 4 to 5 hours; f) diluting the reaction mixture with water at a temperature of 80 0C; g) separating the water phase; h) extracting the organic layer three times with water at a temperature of 80 0C; i) cooling the organic layer to a temperature between 0 and 10 0C while stirring for at least 2 hours; j) collecting the precipitated risperidone (I); k) washing the precipitated risperidone (I) with acetone; and
1) drying the risperidone (I) at a temperature between 50 and 60 0C for 16 to 20 hours.
Risperidone (I) prepared according to the above process does not contain the contaminant product (V) and thus is useful for the preparation of drug product such as risperi- done long acting injection.

Claims

Claims
1. A process for preparing risperidone of formula (I)
Figure imgf000007_0001
comprising the steps of reacting a compoundof formula (IV)
Figure imgf000007_0002
in the presence of a base and a solvent mixture comprising toluene and water, and isolating the risperidone of formula (I) formed during the reaction, characterized in that the reaction is conducted under an atmosphere comprising from 0.1 to 8 % of oxygen.
2. A process according to claim 1 wherein the reaction is conducted at a temperature above 80 0C for 4 to 5 hours.
3. A process according to claim 1 wherein, relative to the amount of the intermediate of formula (IV), the amount of KOH ranges from 4.0 to 4.6 mol/mol; water ranges from 0.25 to 0.35 L/mol; and toluene ranges from 1.3 to 1.5 L/mol.
4. A process according to claim 1 comprising the steps of a) charging a reaction vessel with toluene and KOH; b) adding water to the suspension obtained in step a) while keeping the temperature between 30 and 40 0C; c) adjusting the concentration of oxygen in the atmosphere of the reaction vessel to between 1 and 8 %; d) adding an intermediate of formula (IV) while keeping the temperature above
30 0C; e) heating the reaction mixture to a temperature above 80 0C for 4 to 5 hours; f) diluting the reaction mixture with water at a temperature of 80 0C; g) separating the water phase; h) extracting the organic layer three times with water at a temperature of 80 0C; i) cooling the organic layer to a temperature between 0 and 10 0C while stirring for at least 2 hours; j) collecting the precipitated risperidone (I); k) washing the precipitated risperidone (I) with acetone; and 1) drying the risperidone (I) at a temperature between 50 and 60 0C for 16 to 20 hours.
PCT/EP2008/067691 2007-12-18 2008-12-17 Process for preparing risperidone Ceased WO2009077551A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2007064137 2007-12-18
EPPCT/EP2007/064137 2007-12-18

Publications (1)

Publication Number Publication Date
WO2009077551A1 true WO2009077551A1 (en) 2009-06-25

Family

ID=39495548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/067691 Ceased WO2009077551A1 (en) 2007-12-18 2008-12-17 Process for preparing risperidone

Country Status (1)

Country Link
WO (1) WO2009077551A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206210A (en) * 2011-04-01 2011-10-05 常州市第四制药厂有限公司 Method for producing 6-fluoro-3-(4-piperidine)-1,2-benzoisoxazole hydrochloride

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2006888A6 (en) * 1988-04-08 1989-05-16 Janssen Pharmaceutica Nv Piperidinyl benzo-isoxazole deriv. prepn.
EP0453042A1 (en) * 1990-04-19 1991-10-23 Janssen Pharmaceutica N.V. Novel 2,9-disubstituted-4H-pyrido-[1,2-a]pyrimidin-4-ones
WO2004009591A1 (en) * 2002-07-22 2004-01-29 Aurobindo Pharma Ltd. A process for the preparation of antipsychotic risperidone
US20040097523A1 (en) * 2002-11-13 2004-05-20 Pavel Slanina Process for making risperidone and intermediates therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2006888A6 (en) * 1988-04-08 1989-05-16 Janssen Pharmaceutica Nv Piperidinyl benzo-isoxazole deriv. prepn.
EP0453042A1 (en) * 1990-04-19 1991-10-23 Janssen Pharmaceutica N.V. Novel 2,9-disubstituted-4H-pyrido-[1,2-a]pyrimidin-4-ones
WO2004009591A1 (en) * 2002-07-22 2004-01-29 Aurobindo Pharma Ltd. A process for the preparation of antipsychotic risperidone
US20040097523A1 (en) * 2002-11-13 2004-05-20 Pavel Slanina Process for making risperidone and intermediates therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOMAR R S ET AL: "Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 36, no. 1, 21 September 2004 (2004-09-21), pages 231 - 235, XP004553458, ISSN: 0731-7085 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206210A (en) * 2011-04-01 2011-10-05 常州市第四制药厂有限公司 Method for producing 6-fluoro-3-(4-piperidine)-1,2-benzoisoxazole hydrochloride
CN102206210B (en) * 2011-04-01 2014-07-02 常州市第四制药厂有限公司 Method for producing 6-fluoro-3-(4-piperidine)-1,2-benzoisoxazole hydrochloride

Similar Documents

Publication Publication Date Title
US8044205B2 (en) Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide
JP5341747B2 (en) Synthesis of curcumin
US20180118885A1 (en) Trioxane composition and method for storing same
WO2009077551A1 (en) Process for preparing risperidone
JP5432906B2 (en) Method for synthesizing polyhydroxystilbene compound
JP2001516363A (en) Method for debenzylation of dibenzylbiotin
CA2570833C (en) Process for producing (z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride
US8901361B2 (en) Method for synthesizing 3,5-dichloroanisole from 1,3,5-trichlorobenzene
KR100453590B1 (en) Mono carbonylation of Benzene diols
CN101583586B (en) Improvement in synthesis of butylated hydroxyanisole from tertiary butyl hydroquinone
JP2003327554A (en) 3,3 ', 5,5'-Tetramethyl-4,4'-biphenol and method for producing the same
EP0299893A2 (en) Process for hydroxylating phenols and phenol ethers
JP5078886B2 (en) Method for producing polyamine
EP2860172A1 (en) Method for preparing acetamidophenyl
CA2964818A1 (en) Preparation of sorbate ester
EP1758848A1 (en) Separation of unsymmetrical diimines by liquid chromatography
US20060217574A1 (en) Method for producing 3,3 diallyl-4,4 dihydroxydiphenylsulfone
KR20140067368A (en) Process for preparing eperisone hydrochloride
EP2367828B1 (en) Process for the preparation of tetrazine derivatives
Groundwater et al. Photolysis of fluorodiphenylamines
SU968030A1 (en) Process for purifying 2-mercaptopropylamine or its hydrochloride
JP3861298B2 (en) Nuclear t-butylation process for pyrogallol
EP0812842A2 (en) Process for the preparation of 5-(alkoxymethyl)-2,3-pyridine-dicarboximide compounds
JP2009149543A (en) 4- [1 ′, 2 ′, 3 ′, 4 ′, 4′a, 9′a-Hexahydro-6′-hydroxyspiro (cyclohexane-1,9′-xanthene) -4′a-yl] resorcinol Method
JP2010090102A (en) Method for producing cyclic compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08862495

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08862495

Country of ref document: EP

Kind code of ref document: A1